Endo International PLC (ENDP)

ENDP (NASDAQ:Drugs) EQUITY
$16.26
pos +0.07
+0.43%
Today's Range: 15.20 - 16.30 | ENDP Avg Daily Volume: 10,021,400
Last Update: 06/29/16 - 2:18 PM EDT
Volume: 11,428,807
YTD Performance: -73.55%
Open: $16.22
Previous Close: $16.19
52 Week Range: $12.56 - $88.54
Oustanding Shares: 222,661,344
Market Cap: 3,048,233,799
6-Month Chart
TheStreet Ratings Grade for ENDP
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 7 6
Moderate Buy 1 1 1 1
Hold 11 10 8 8
Moderate Sell 0 0 0 0
Strong Sell 0 1 0 0
Mean Rec. 2.35 2.47 2.06 2.13
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 4.03
Price Earnings Comparisons:
ENDP Sector Avg. S&P 500
4.03 0.00 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-42.73% -79.97% -55.99%
GROWTH 12 Mo 3 Yr CAGR
Revenue 13.60 0.10 0.03
Net Income 0.00 -0.60 0.00
EPS 0.00 0.20 0.00
Earnings for ENDP:
EBITDA 1.01B
Revenue 3.27B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.84 $1.11 $4.59 $4.94
Number of Analysts 10 10 11 10
High Estimate $1.09 $1.25 $4.66 $5.30
Low Estimate $0.72 $0.94 $4.51 $4.55
Prior Year $1.08 $1.02 $4.87 $4.59
Growth Rate (Year over Year) -22.13% 8.73% -5.81% 7.58%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
ENDP shares surge on rare good news but asset sales may still be necessary.
Optimism that the United Kingdom will remain part of the EU was tempered by falling oil prices.
Problems with mesh products and high leverage might scare away a potential buyer. 
Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.
Bearish
May 06, 2016 | 7:42 AM EDT
ENDP was downgraded from Outperform to Sector Perform, RBC Capital said. $26 price target. Turnaround is going to take longer than expe...
The specialty pharmaceutical company gave investors a lot of news to digest -- and they fled.
the Sale of ASTORA Women's Health could bode well for the speciality pharma, as legal woes persist.
Mylan and Endo International look like bargains at current prices.
These biotech/pharma picks could give you a very happy new year.
The company cleared an important hurdle last month.

Columnist Conversations

There is just not much to get excited about when looking at individual stock charts. I scanned about 80 diffe...
General Mills (GIS) surprised investors with a much better than expected 4th quarter today. Revenues were bett...
We still have to take this market one decision to the next.  The last decision was the key symmetry support a...
The huge bounce back rally continues. Sequential Brands Group (SQBG), one of my buys on the Brexit dip now ha...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.